Preclinical studies have supported the activity of rapamycin analogues CCI 779 (temsirolimus) and RAD-001 (everolimus) in breast cancer cells with activated Akt and showed that the addition of everolimus reduced proliferation by a further 50% compared with letrozole alone (Farmer et al, 2005). This evidence concerns the gene AKT1 and breast carcinoma.